+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Alpha-Adrenoceptor Stimulation and Calcium Movements


      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          A survey is given of the interaction between α-adrenoceptor-triggered vasoconstriction and the influx of extracellular calcium ions. This problem was investigated by studying the influence of calcium entry blockers (CEB) on the vasoconstriction, induced by several types of α<sub>2</sub>- and α<sub>1</sub>-adrenoceptor agonists, both in vivo and in vitro. In addition, experiments were performed with the calcium entry promoter Bay K 8644. α<sub>2</sub>-Adrenoceptor-triggered vasoconstriction is invariably accompanied by an influx of extracellular calcium ions which substantially contributes to the initiation of vascular smooth muscle contraction. This concept is a very general phenomenon, which holds for a variety of α<sub>2</sub>-adrenoceptor agonists and CEB, in vivo and in vitro, and in different animal species. The α<sub>1</sub>-adrenoceptor-induced vasoconstriction appears to be caused both by the release of intracellular calcium and by the transmembranous influx of intracellular calcium. The ratio between both processes is very different, depending upon the type of α<sub>1</sub>-adrenoceptor agonist and on the experimental preparation used. It has been speculated that this ratio can be influenced by phenoxybenzamine.

          Related collections

          Author and article information

          J Vasc Res
          Journal of Vascular Research
          S. Karger AG
          23 September 2008
          : 24
          : 5
          : 271-280
          aDivision of Pharmacotherapy, University of Amsterdam, The Netherlands; bDivision of Cardiovascular Diseases, Biomedical Products Department, Dupont de Nemours &amp; Co. Inc., Wilmington, Del., USA
          158703 Blood Vessels 1987;24:271–280
          © 1987 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 10

          General medicine,Neurology,Cardiovascular Medicine,Internal medicine,Nephrology
          Calcium entry blockers,Phenoxybenzamine,Calcium fluxes,Bay K 8644,Alpha-adrenoceptors


          Comment on this article